AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

 AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

Shots:

  • AbbVie has resolved the Humira litigation with BI, granting BI non-exclusive rights to BI for Humira’s IPR in the US
  • BI will pay royalties for licensing HUMIRA patents and acknowledges the validity and enforceability of the licensed patents
  • The initiation of the license will begin from Jul,1 2023

Click here to read full press release/ article | Ref: AbbVie| Image: Modern Healthcare

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post